Cited by 780HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Open access

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, Solit, David B.·2018·Nature

DOI 10.1038/nature25475PMC PMC5808581

Open this paper in CoChat — free account

Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature25475

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

KEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9984 · Cited by 4,080
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777

Show all 54 references

Sorted by citations

Items 701–779 of 779

Data from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Jhaveri, K. L., Chang, M. T., Juric, D., Saura, C., Gambardella, V., Melnyk, A., Patel, M. R., Ribrag, V., Ma, C. X., Aljumaily, R. M., et al. (2023) · doi:10.1158/1078-0432.c.6530237.v1
Self-citation
Data from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Ma, C. X., Luo, J. R., Freedman, R. A., Pluard, T., Nangia, J. R., Lu, J. M., Valdez-Albini, F., Cobleigh, M., Jones, J. M., Lin, N., et al. (2023) · doi:10.1158/1078-0432.c.6532574.v1
Self-citation
Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Lenoue-Newton, M. L., Chen, S., Stricker, T. P., Hyman, D. M., Blauvelt, N., Bedard, P. L., Meric‐Bernstam, F., Punglia, R. S., Schrag, D., Lepisto, E. M., et al. (2023) · doi:10.1158/1078-0432.c.6531065.v1
Self-citation
Data from Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers
Horak, P., Heining, C., Kreutzfeldt, S., Hutter, B., Möck, A., Hüllein, J., Fröhlich, M., Uhrig, S., Jahn, A., Rump, A., et al. (2023) · doi:10.1158/2159-8290.c.6549421.v1
Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Meric‐Bernstam, F., Ford, J. M., O'Dwyer, P. J., Shapiro, G. I., McShane, L. M., Freidlin, B., O'Cearbhaill, R. E., George, S., Bender, J. G., Lyman, G. H., et al. (2023) · doi:10.1158/1078-0432.c.6533210.v2
Self-citation
Entitätsagnostische Tumortherapie – Was spricht dafür, was dagegen?
Desuki, A., Pretzell, I., Kloth, M. T., & Paret, C. (2023) · TumorDiagnostik & Therapie · doi:10.1055/a-1917-4870
Autres cibles addictives (KRAS, RET, HER2, NTRK…)
Planchard, D., Simon, É., Abdayem, P., & Greillier, L. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00140-4
The uncharted role of HER2 mutant alleles in breast cancer
Kalra, R., Lim, B., Ellis, M. J., & Kavuri, S. M. (2023) · Oncotarget · doi:10.18632/oncotarget.28489
Tumor Mutation Burden as a Marker for Molecularly Matched Therapy: More Evidence Needed
Meng, X., & Wu, Q. (2023) · Epigenomics · doi:10.2217/epi-2023-0354
Cracking the Code: Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive ReviewPreprint
Sinha, B. K. (2023) · Preprints.org · doi:10.20944/preprints202312.1293.v1
Development of Nomogram for Predicting Axillary Pathologic Complete Response after Neoadjuvant Therapy in Breast Cancer Patients without Distant Metastasis
Zhang, J., Cao, H., Wang, G., Nie, C.-B., Bai, S.-M., & Ma, S. (2024) · Journal of Cancer Science and Clinical Therapeutics · doi:10.26502/jcsct.5079224
Research Progress in Clinical Therapeutic Efficacy and Safety of HER2-Positive Non-Small Cell Lung Cancer
李, 倩. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141311
Targeting HER2 / HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy
Blas, P. E., Rodriguez, E. S. R., Williams, H. L., Levin, M. K., Bell, J. S. K., Pierobon, M., Barrett, A. S., Petricoin, E. F., & O’Shaughnessy, J. (2024) · Cancer Reports · doi:10.1002/cnr2.1954
Additional file 1 of Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies
Liu, L., Wu, M., Huang, A., Gao, C., Yang, Y., Liu, H., Jiang, H., Yu, L., Huang, Y., & Wang, H. (2023) · Figshare · doi:10.6084/m9.figshare.24115064
Comprehensive Genomic Profiling of Taiwanese Breast Cancer Using a Novel Targeted Sequencing PanelPreprint
Huang, C., Yeh, Y., Liu, C., Tsai, Y., Ho, H., & Tseng, L. (2024) · Research Square · doi:10.21203/rs.3.rs-4180298/v1
Dynamic changes in tumor profiling reveal intra- and inter-tumoral heterogeneity focused on an uncharacterized HER2 mutation: a case report of a young breast cancer patient
Schaffrin-Nabe, D., Josten-Nabe, A., Tannapfel, A., Uhl, W. H., Garmer, M., Kurzrock, R., Crook, T., Limaye, S. A., Schuster, S., Patil, D., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1395618
Exploring the Potential of Nanomolecular Therapeutic Options and Novel Biomarkers in Triple-negative Breast Cancer Treatment
Verma, R., Jain, Y., Rani, L., Kaushik, D. K., Bhatt, S., & Mathur, P. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947297237240530055719
Clinical implications of resistance to anti-HER2 antibodies in breast cancer
Dhanisha, S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-816408-2.00005-1
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy, F. M., Turner, A. L., Marensi, V., & MacEwan, D. J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1441938
Autres cibles addictives (KRAS, RET, HER2, NTRK...)
Cortot, A. B., Abdayem, P., & Planchard, D. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00090-9
Interplay of Cardiometabolic Syndrome and Biliary Tract Cancer: A Comprehensive Analysis with Gender-Specific Insights
Stasi, V. D., Contaldo, A., Birtolo, L. I., & Shahini, E. (2024) · Cancers · doi:10.3390/cancers16193432
Paired CRISPR screens to map gene regulation in cis and transPreprint
Xue, X., Gajic, Z. Z., Caragine, C. M., Legut, M., Walker, C. R., Kim, J. Y. S., Wang, X., Yan, R., Wessels, H., Lu, C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625752
From a broad pan-cancer analysis towards personalized therapy
Küçükosmanoğlu, A. (2025) · doi:10.5463/thesis.930
Bayesian Hierarchical Model with Adaptive Similarity Evaluation of Treatment Effects in Oncology Basket Trials
Kitabayashi, R., Sato, H., Nomura, S., & Hirakawa, A. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2455562
Molecularly Targeted Therapy for Gallbladder Cancer
Pierce, K., & Gomez, C. (2024) · Springer eBooks · doi:10.1007/978-3-031-76746-3_16
Targeting HER2 in metastatic urothelial carcinoma: a contemporary review
Jang, A., Ghimirey, N., Kumar, H. L. S., Mendiratta, P., Rao, S. K., Sheng, I. Y. F., Barata, P. C., Garcia, J. A., & Brown, J. R. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2024-0580
85P Comprehensive genomic profiling of Taiwanese triple-negative breast cancers with medium- and large-sized sequencing panels: A comparative study implicating treatment allocations
Huang, C.-C., Yeh, Y.-C., Tsai, Y.-F., Lin, Y., Chao, T.-C., Liu, C.-Y., Ho, H., & Tseng, L.-M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104639
Figure S1-S10 from Targeting the Dependence on PIK3C3-mTORC1 Signaling in Dormancy-Prone Breast Cancer Cells Blunts Metastasis Initiation
Elkholi, I. E., Robert, A., Malouf, C., Wu, J., Kuasne, H., Drápela, S., MacLeod, G. D. A. H., Hébert, S., Pacis, A., Calderon, V., et al. (2025) · doi:10.1158/0008-5472.29326834
Targeted Therapy in NSCLC: A Comprehensive Review of Molecular Drivers and Treatment Strategies
Milasheuskaya, V., Miraniuk, K., Sobchynskyi, M., Myrnyi, A., Kowalczuk, D., Kasianik, V., Lazitskaya, D., Turlej, K., Kiełbaszewska, I., Surosz, N., et al. (2025) · Quality in Sport · doi:10.12775/qs.2025.43.61191
Epigenetic Regulation and Targeted Therapy in Gall Bladder Cancer
Singh, D., & Mukherjee, S. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70403
A Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) with Clinical Cohort and in vitro Validation
Liu, Y., Liu, J., Li, Y., Zhao, Z., Lyu, D., Dong, K., Wei, M., Huang, R., Lu, B., & Pan, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s515347
Comprehensive genomic profiling of Taiwanese triple‑negative breast cancer samples with medium‑ and large‑sized sequencing panels: A comparative study implicating treatment allocations
Huang, C.-C., Yeh, Y., Tsai, Y., Lin, Y., Chao, T., Liu, C., Ho, H., & Tseng, L. (2025) · Biomedical Reports · doi:10.3892/br.2025.2040
Scandare: A Successful, Flexible, Prospective, and Longitudinal Biobank FrameworkPreprint
Tourneau, C. L., Lamy, C., Lecompte, L., Dupain, C., Nicolas, P.-A., Chanas, L., Nguyen, V., Berger, F., Kadi, A., Caputo, S. M., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7354298/v1
Human Epidermal Growth Factor Receptor 2 [ HER ‐2/neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran
Salarvand, S., Mohammadi, A., Shahsiah, R., Bagheri, F., Gholizadeh, M., vangah, S. J., Esmati, E., Lashkari, M., Soleymani, V., Zareh‐Dehabadi, S., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70314
HER2-low status as a dynamic biomarker in breast cancer: molecular and clinical correlations
Stukan, А. I., Vtorushin, S. V., Bogdan, A. P., Semiglazova, Т. Y., Kudrina, V. V., Bodnya, V. N., Porkhanov, V. A., Dovlatbekyan, A. A., Chagiev, M. A., & Naniz, A. A. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2025-24-4-29-42
Cancer bronchique non à petites cellules avec autres mutations actionnables (BRAF, MET, HER2)
Mogenet, A., Cortot, A. B., Abdayem, P., Planchard, D., & Greillier, L. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00079-5
Efficacy and safety of pyrotinib in patients with previously treated HER2-positive non-breast solid tumors: a phase 2, open-label basket trial
Zhou, H., Lv, M., Li, W., Wang, Y., Wu, J., Liu, Q., Liu, T., & Li, Q. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf341
An Update on Therapeutic Strategies for HER2-Mutated Non-Small Cell Lung Cancer
Ishihara, M., Tanzawa, S., Honda, T., Ichikawa, Y., Watanabe, K., & Seki, N. (2025) · Journal of Clinical Question · doi:10.69854/jcq.2025.0029
Phase I trial of neratinib plus palbociclib in advanced cancers with HER family alterations
Piha-Paul, S. A., Tseng, C., Tran, H. T., Fu, S., Dumbrava, E. E. I., Yap, T. A., Naing, A., Lim, J. Y., Murphy, M. B., Ramirez, D. L., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105895
Self-citation
Additional file 2 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599365
Additional file 4 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599371
Additional file 5 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599374
Additional file 1 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599362
Additional file 7 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599380
Additional file 1 of Biomarker discovery with quantum neural networks: a case-study in CTLA4-activation pathways
Nguyen, P.-N. (2024) · Figshare · doi:10.6084/m9.figshare.25596425
Additional file 3 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599368
Additional file 6 of Changes in HER3 expression profiles between primary and recurrent gynecological cancers
Kojima, Y., Sudo, K., Yoshida, H., Yazaki, S., Tokura, M., Mizoguchi, C., Okuma, H. S., Kita, S., Yamamoto, K., Nishikawa, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22599377
Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan
Ogura, N., Hirano, H., Shiraishi, K., Fujii, H., Hirose, T., Shoji, H., Okita, N. T., Takashima, A., Koyama, T., Yonemori, K., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-00562
Triple-positive non-small cell lung cancer harboring EGFR mutation, ALK rearrangement, and high PD-L1 expression: a case report and literature review
Mao, M., Tao, Q., Zuo, Z., Ge, J., Tian, Y., & Liu, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1727899
Genomic profiling and HER2-targeted therapy: a case series of Chinese salivary duct carcinoma patients and its clinical implications
Huang, X. S., Yu, W., Li, X., Cai, B., Qu, B., Chen, J., Zhang, P., Chen, X., Liu, Y., Feng, S., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1727362
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2 -mutant solid tumors
Schram, A. M., Park, J., Italiano, A., Kitano, S., Guo, Y. P., Li, J., Bedard, P. L., Marcke, C. V., Ko, R., Lunger, L., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2637740
Self-citation
pKAKA: a protein language model for prioritizing kinase-disrupting variants in diseases.
Li, J.-T., Cheng, H.-Y., Liang, Z., Hu, J., Chu, Y.-T., Cai, R., Cao, B., Jin, Y., Xie, Y., Ju, H.-Q., et al. (2026) · Journal of genetics and genomics = Yi chuan xue bao · doi:10.1016/j.jgg.2026.03.010
Recurrent Epidermal Growth Factor Receptor 2 (ERBB2) Mutations Drive the Pathogenesis of Multifocal Neurofibroma Variants
Yeung, M. C., Lefkowitz, R. A., & Antonescu, C. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.100992
A North American Collaborative Atlas of Oncology Data Visualization with R Statistical SoftwarePreprint
Soltanifar, M., Portuguese, A. J., Jeon, Y., Gauthier, J., & Lee, C. H. (2026) · medRxiv · doi:10.64898/2026.03.20.26348936
Caractérisation moléculaire et étude des conséquences fonctionnelles des mutations somatiques du gène NF1 dans les carcinomes bronchiques non à petites cellules
Tlemsani, C. (2018) · theses.fr (ABES) · doi:10.70675/8f53e2e3z34d1z4c4bz80cfz5afce9d3ade3
Spécificités moléculaires des tumeurs urothéliales de la voie excrétrice urinaire supérieure
Audenet, F. (2019) · doi:10.70675/0cfa19e5z9a93z4b1dza3aezdff92afb5f97
Contribution à l'identification de marqueurs de la réponse des carcinomes bronchiques non à petites cellules aux immunothérapies
Guisier, F. (2019) · theses.fr (ABES) · doi:10.70675/9de2ee5az6556z48b7z97b1zc402c970fc69
Comprehensive genomic profiling in solid tumours: Navigating promise, challenges, and pathways to clinical integration
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127
Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
Figarol, S. (2020) · theses.fr (ABES) · doi:10.70675/9b097a88z7be2z4f00z913fze60d534fa601
Precision therapy for driver gene mutations in breast cancer: Current landscape and future perspectives
Liu, Z.-Y., & Chen, R. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i4.117540
Targeting HER2 in advanced non-small cell lung cancer: The emerging role of zongertinib
Pallas, C. R., Carrizosa, D. R., & Mileham, K. F. (2026) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2026.22.1.6
Pertuzumab and Trastuzumab in Patients With ERBB2/3 -Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study
Chan, J. K., Rothe, M., Garrett-Mayer, E. S., Pisick, E. P., Ghatalia, P., Gregory, A., deShazo, M., Mileham, K. F., Murphy, M. C., Alese, O. B., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01250
Applications and Innovations in High-Throughput Sequencing: Thoracic Pathology
Perrone, G., & Nibid, L. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_6
From Biopsy to Biology: Next-Generation Sequencing in Endometrial, Ovarian, and Cervical Carcinoma
Vellone, V. G., Gaggero, G., & Paudice, M. (2026) · Current clinical pathology · doi:10.1007/978-3-032-18790-1_9
Unleashing Precision Oncology in the Development of Human Epidermal Growth Factor Receptor 2–Targeted Antibody Drug Conjugates for Urothelial Carcinoma
McGregor, B. A., & Sonpavde, G. (2026) · JCO Precision Oncology · doi:10.1200/po-26-00110
The State of the Art and the Future of Precision Medicine: A Comprehensive Literature Review
Abu‐Jeyyab, M., Dahoud, S., Habash, A., Qura’an, B., Al-Jafari, M., Mse’adeen, M. A., Elqadah, B., Hamdan, A., Allauzy, E., & Dogheim, G. M. (2026) · High Yield Medical Reviews · doi:10.59707/hymryawo7926
Production, purification, and crystallization of the recombinant HER2 tyrosine kinase domain (HER2-TKD)
Topalan, E., Ciftci, H. I., & DeMi̇rci̇, H. (2026) · TURKISH JOURNAL OF CHEMISTRY · doi:10.55730/1300-0527.3794
HER2 assessment in urothelial carcinoma: standardization challenges and the path forward
Xie, P. Y., Wang, Y., Lu, L., Chen, J., Wei, J., Huang, Y., Guo, C., Li, J., Yan, X., Guo, J., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10353-y
Afatinib for Advanced Cancers Carrying an EGFR, HER2, or HER3 Mutation: An Open-Label, Phase II, Belgian Precision Study
Decoster, L., Aftimos, P. G., Rottey, S., Prenen, H., Collignon, J., Mebis, J., Canon, J. L., Fastenaekels, V., Cappoen, N., Kondrat, A., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01198
First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial
Yang, Y., Jiang, W., Yang, G., Li, W., Li, J., Hao, X., Xing, P., Lei, S., Wei, F., Tian, L., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109589
Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer (RERUN): Study Protocol for a Real-World, Multicenter, Prospective, Observational Study
Duan, J., Zhuo, M., Su, C., Liu, Y., Wang, L., Yang, N., Cao, B., Hu, M., Jin, S., Li, H., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03729-7
Primary Cutaneous Apocrine Carcinoma: Clinicopathologic, Immunohistochemical, and Molecular Characterization of 27 Cases
Moran, J. M. T., Shore, K. T., Dias-Santagata, D., Laga, A. C., Hosler, G. A., Fujimoto, M., Mochel, M. C., & Hoang, M. P. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101082
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
Zhang, H., Ma, D., Li, F., Shao, Z., & Chen, C. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3311-5
Clinicopathologic and Molecular Insights Into ERBB2-Altered S100/SOX10-Positive Uterine Sarcoma: A Report of 6 Cases
Lyu, Z., Han, W., Li, H., Liang, X., Su, X., & Wu, H. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101087
Immunohistochemical evaluation of human epidermal growth factor receptor 2 expression in salivary gland malignancies
Raj, K. B., Joseph, L. A. I., Premalatha, B., Ramadoss, K., Veeravarmal, V., & Amuthan, S. (2026) · Journal of Oral and Maxillofacial Pathology · doi:10.4103/jomfp.jomfp_289_25
BindingDB Entry 50021708: Discovery of Novel 5,6-Dihydro-4H-pyrido[2,3,4-de]quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases.
BindingDB (2025) · UC San Diego · doi:10.7270/q2bk1j0k
HER2 mutation in metastatic breast cancer
ma, F. (2020) · China National GeneBank DataBase · doi:10.26036/cnp0001305
HER2/ERBB2 and Genomic Alterations in Patients with Gallbladder Cancer from Argentina
Arroyo, G. F., Haab, G. A., Avila, A., Abidoye, O., Raupach, E. A., Braggio, E., & Borad, M. J. (2026) · Cancers · doi:10.3390/cancers18213461
Pan-Gynecologic Cancer Analysis of ERBB2 Gene Mutations Across More Than 21,000 Tumor Samples
Ahsan, M. D., Gysler, S. M., Ko, E., Guintoli, R. L., Kim, S. H., Latif, N., & Nasioudis, D. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105679

Authors: Hyman, D. M., Piha-Paul, S. A., Won, H., Rodon, J., Saura, C., Shapiro, G. I., Juric, D., Quinn, D. I., Moreno, V., Doger, B., Mayer, I. A., Boni, V., Calvo, E., Loi, S., Lockhart, A. C., Erinjeri, J. P., Scaltriti, M., Ulaner, G. A., Patel, J., Tang, J., Beer, H., Selcuklu, S. D., Hanrahan, A. J., Bouvier, N., Melcer, M., Murali, R., Schram, A. M., Smyth, L. M., Jhaveri, K., Li, B. T., Drilon, A., Harding, J. J., Iyer, G., Taylor, B. S., Berger, M. F., Cutler Jr, R. E., Xu, F., Butturini, A., Eli, L. D., Mann, G., Farrell, C., Lalani, A. S., Bryce, R. P., Arteaga, C. L., Meric-Bernstam, F., Baselga, J., & Solit, D. B.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
Vall d'Hebron Hospital Universitari (ES)
Dana-Farber Cancer Institute (US)
USC Norris Comprehensive Cancer Center (US)
Vanderbilt University (US)
Peter MacCallum Cancer Centre (AU)
Washington University in St. Louis (US)
Puma Biotechnology (United States) (US)
Corresponding author: Hyman, David M.
ORCID: Hyman, David M.
Piha-Paul, Sarina A.
Won, Helen
Rodon, Jordi
Saura, Cristina
Shapiro, Geoffrey I.
Juric, Dejan
Quinn, David I.
Mayer, Ingrid A.
Boni, Valentina
Calvo, Emiliano
Loi, Sherene
Lockhart, Albert C.
Erinjeri, Joseph P.
Scaltriti, Maurizio
Ulaner, Gary A.
Patel, Juber
Bouvier, Nancy
Murali, Rajmohan
Schram, Alison M.
Smyth, Lillian M.
Jhaveri, Komal
Li, Bob T.
Drilon, Alexander
Harding, James J.
Iyer, Gopa
Taylor, Barry S.
Berger, Michael F.
Xu, Feng
Eli, Lisa D.
Lalani, Alshad S.
Bryce, Richard P.
Arteaga, Carlos L.
Solit, David B.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2018-01-31
Volume: 554
Issue: 7691
Pages: 189-194
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature25475
PMC: PMC5808581
OpenAlex: W2785610956
Cited by: 780
References: 54
Citations by year: 2026: 40 · 2025: 64 · 2024: 89 · 2023: 99 · 2022: 113 · 2021: 103 · 2020: 113 · 2019: 86 · 2018: 69
FWCI: 34.53
Type: journal article
Language: en
Update notices: correction (2019-02-12)
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Funders: Puma Biotechnology
National Institutes of Health (UL1TR000371)
National Cancer Institute (R01CA204749, U01CA180964, R01CA080195, P50CA098131, P30CA008748, P30CA016672, T32CA009207, R25CA020449, P30CA014089)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, ERBB2, HER3, neratinib, basket trials, breast cancer, biliary tract cancer, cervical cancer, targeted therapy
MeSH terms: Adult, Aged, Aged, 80 and over, Alleles, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Neoplasms, Quinolines, Cohort Studies, Treatment Outcome, Erb-b2 Receptor Tyrosine Kinases, Mutation, Missense, Receptor, ErbB-3, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks